KR850001693A - 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법 - Google Patents

아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법 Download PDF

Info

Publication number
KR850001693A
KR850001693A KR1019840005306A KR840005306A KR850001693A KR 850001693 A KR850001693 A KR 850001693A KR 1019840005306 A KR1019840005306 A KR 1019840005306A KR 840005306 A KR840005306 A KR 840005306A KR 850001693 A KR850001693 A KR 850001693A
Authority
KR
South Korea
Prior art keywords
hydrochloride
mixture
enteric material
amosulolol
preparing
Prior art date
Application number
KR1019840005306A
Other languages
English (en)
Other versions
KR910002670B1 (ko
Inventor
다까시(외 4) 소노베
Original Assignee
모리오까 시게오
야마노우치 팔마세티칼 코포레이션, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모리오까 시게오, 야마노우치 팔마세티칼 코포레이션, 리미티드 filed Critical 모리오까 시게오
Publication of KR850001693A publication Critical patent/KR850001693A/ko
Application granted granted Critical
Publication of KR910002670B1 publication Critical patent/KR910002670B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예 1에서 제조된 본 발명의 지속성 제제및 아모술랄롤 하이드로 클로라이드의 통상적인 제제를 경구투여할 때 단일-맹시험 교차 연구에 의한 시간에 따른 아모술랄롤 하이드로클로라이드의 혈장 수준을 나타낸다.
제2도는 실시예 2에서 제조된 본 발명의 지속성 제제 및 아모술랄롤 하이드로클로라이드의 통상적인 제제를 경구투여할때 단일-맹시험 교차연구에 의한 시간에 따른 아모술랄롤 하이드로클로라이드의 혈장 수준을 나타낸다. 비글종개 5마리의 평균치.
제3도는 실시예 3에서 제조된 본 발명의 지속성 제제 및 아모술랄롤 하이드로클로라이드의 수용액을 경구투여할때 단일-맹시험 교차연구에 의한 시간에 따른 아모술랄롤 하이드로 클로라이드의 혈장 수준을 나타낸다. 비글종개 6마리의 평균치.

Claims (5)

  1. 아모술랄롤 하이드로클로라이드 또는 아모술랄롤하이드로 클로라이드부형제의 혼합물에 장용성 물질 또는 물 또는 유기용매중 그의 용액 또는 현탁액을 가하고, 필요하다면 결합제를 사용하여 혼합물을 과립화시키고, 생성된 과립을 정제기로 타정함을 특징으로 하여 아모술랄롤 하이드로클로라이드 지속성 제제를 제조하는 방법.
  2. 제1항에 있어서, 장용성 물질이 메타크릴산 에틸 아크릴레이트 공중합체인 방법.
  3. 아모술랄롤 하이드로클로라이드 또는 아모술랄롤하이드로 클로라이드 및 부형제의 혼합물에 장용성 물질 또는 물 또는 유기용매중 그의 용액 또는 현탁액을 가하고, 장용성 물질의 첨가전 또는 후에 아모술랄롤 하이드로클로라이드 또는 아모술랄롤 하이드로 클로라이드와 부형제의 혼합물에 약제학적으로 무독한 유기산 또는 그의 용액을 가하고, 필요하다면, 결합제를 사용하여 이 혼합물을 과립화시키고, 생성된 과립을 정제기로 타정함을 특징으로 하여 아모술랄롤 하이드로클로라이드지속성 제제를 제조하는 방법.
  4. 제3항에 있어서, 장용성 물질이 메타크릴산·에틸-아크릴레이트 공중합체인 방법.
  5. 제3항에 있어서, 약제학적으로 무독한유기산이 시트르산 또는 타르타르 산인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019840005306A 1983-08-31 1984-08-30 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법 KR910002670B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP58-160086 1983-08-31
JP58160086A JPS6051106A (ja) 1983-08-31 1983-08-31 塩酸アモスラロ−ル持続性製剤
JP160086 1983-08-31

Publications (2)

Publication Number Publication Date
KR850001693A true KR850001693A (ko) 1985-04-01
KR910002670B1 KR910002670B1 (ko) 1991-05-03

Family

ID=15707557

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840005306A KR910002670B1 (ko) 1983-08-31 1984-08-30 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법

Country Status (7)

Country Link
US (2) US4724148A (ko)
EP (1) EP0136103B1 (ko)
JP (1) JPS6051106A (ko)
KR (1) KR910002670B1 (ko)
AT (1) ATE57833T1 (ko)
DE (1) DE3483504D1 (ko)
ES (1) ES8602406A1 (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
ES2077023T3 (es) * 1989-03-10 1995-11-16 Yamanouchi Pharma Co Ltd Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
US5258186A (en) * 1989-03-10 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Drug release controlling coating material for long acting formulations
EP0447168A3 (en) * 1990-03-16 1993-01-07 Yamanouchi Pharmaceutical Co. Ltd. Long acting granular pharmaceutical composition
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
JP3426230B2 (ja) * 1991-05-20 2003-07-14 アベンティス・ファーマスーティカルズ・インコーポレイテッド 複数層の制御放出処方剤
FR2737494B1 (fr) * 1995-08-04 1997-08-29 Synthelabo Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
WO1999057131A1 (en) * 1998-05-06 1999-11-11 Duke University Method of treating bladder and lower urinary tract syndromes
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
AU1169601A (en) * 1999-11-16 2001-05-30 Ranbaxy Laboratories Limited Taste masked oral compositions
JP4494712B2 (ja) * 2002-11-12 2010-06-30 大日本住友製薬株式会社 マルチプルユニット型徐放性製剤
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
EP2180882B2 (en) 2007-10-19 2017-06-28 Otsuka Pharmaceutical Co., Ltd. Solid matrix pharmaceutical preparation
DE102011012517A1 (de) * 2011-02-25 2012-08-30 Renolit Ag Verfahren zum Schutz von Oberflächen vor Bewuchs
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT270071B (de) * 1966-08-12 1969-04-10 Roehm & Haas Gmbh Dragierlack für Arzneiformen
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
US3784683A (en) * 1971-03-29 1974-01-08 Abbott Lab Tablet preparation
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
JPS535728B2 (ko) * 1974-01-12 1978-03-01
CA1097220A (en) * 1975-10-10 1981-03-10 Aaron L. Weiss Controlled release tablet
CA1147342A (en) * 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4289750A (en) * 1978-10-16 1981-09-15 Kopp Klaus F Therapy of conditions which may be associated with altered renal function and dosage forms therefor
JPS606330B2 (ja) * 1978-11-30 1985-02-18 山之内製薬株式会社 α・β両遮断剤
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤

Also Published As

Publication number Publication date
US4765988A (en) 1988-08-23
JPS6051106A (ja) 1985-03-22
JPH0443049B2 (ko) 1992-07-15
ES535545A0 (es) 1985-12-01
EP0136103A2 (en) 1985-04-03
DE3483504D1 (de) 1990-12-06
EP0136103B1 (en) 1990-10-31
ATE57833T1 (de) 1990-11-15
EP0136103A3 (en) 1986-10-22
US4724148A (en) 1988-02-09
ES8602406A1 (es) 1985-12-01
KR910002670B1 (ko) 1991-05-03

Similar Documents

Publication Publication Date Title
KR850001693A (ko) 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법
EP0214735B1 (en) Controlled release pharmaceutical composition
KR890001526A (ko) 경구용 서방성 아세트 아미노펜 제형 및 이의 제조방법
KR880010757A (ko) 제약정제, 제약과립 및 그의 제조방법
DK0721330T3 (da) Farmaceutisk præparat
NZ336789A (en) Use of methacrylic acid copolymer type C in the manufacture of tablets
KR880010759A (ko) 방출 조절성 제제
KR880004804A (ko) 분무건조 아세트 아미노펜
KR900012606A (ko) 이중 정제
ATE244004T1 (de) Pharmazeutische zubereitung enthaltend metformin und verfahren zu deren herstellung
EA199800775A1 (ru) Таблетки, содержащие бетта-лактамный антибиотик, и способ их изготовления
KR890004686A (ko) 서방성 에토돌락
DK0525389T3 (da) Fremgangsmåde til fremstilling af mekanisk stabile, let henfaldende tabletter af formlegemer, som indeholder aktivt stof
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
KR880010758A (ko) 서방성 제제
KR880009639A (ko) 서방성 매트릭스 제형
ATE77236T1 (de) Pharmazeutische zusammensetzungen.
DE69112914D1 (de) Herstellungsverfahren von Mikrokugeln.
SE8204581D0 (sv) New pharmaceutical sustained-release compositions
DE69034226D1 (de) Herstellungsverfahren von Huperzine A und deren Analogen und Verbindungen nützlich dazu
KR860002270A (ko) 니트렌디핀을 함유하는 고상 약제 및 그의 제조방법
SE8901003D0 (sv) Snabbloesliga preparat
EA200300247A1 (ru) Фармацевтическая композиция, содержащая циталопрам
DK1227797T3 (da) Farmaceutiske faststofdispersionsformuleringer
JPS5726615A (en) Improving method for absorbability of slightly soluble drug

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee